For the quarter ended March 2025, Teleflex (TFX) reported revenue of $700.67 million, down 5% over the same period last year. EPS came in at $2.91, compared to $3.21 in the year-ago quarter.
The reported revenue represents a surprise of +0.22% over the Zacks Consensus Estimate of $699.13 million. With the consensus EPS estimate being $2.88, the EPS surprise was +1.04%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- Americas: $475.70 million versus $418.41 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change.
- Geographic Revenues- Asia: $73.80 million compared to the $77.13 million average estimate based on eight analysts.
- Geographic Revenues- EMEA: $151.20 million versus $154.16 million estimated by eight analysts on average.
- Net Revenues- Interventional: $137.50 million versus $137.85 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.
- Net Revenues- Interventional Urology: $71 million versus the 12-analyst average estimate of $69.11 million. The reported number represents a year-over-year change of -10.9%.
- Revenues- OEM (Original Equipment Manufacturer and Development Services): $63.90 million versus the 12-analyst average estimate of $70.27 million. The reported number represents a year-over-year change of -27.1%.
- Net Revenues- Vascular Access: $182.40 million versus $178.12 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a +0.6% change.
- Net Revenues- Anesthesia: $86.60 million compared to the $92.40 million average estimate based on 12 analysts. The reported number represents a change of -10.2% year over year.
- Net Revenues- Other: $53.50 million compared to the $49.30 million average estimate based on 12 analysts. The reported number represents a change of +2.1% year over year.
- Net Revenues- Surgical: $105.80 million compared to the $102.08 million average estimate based on 12 analysts. The reported number represents a change of +0.3% year over year.
View all Key Company Metrics for Teleflex here>>>
Shares of Teleflex have returned -3.1% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teleflex Incorporated (TFX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
